Two new immunoassays, a lateral flow immunoassay (LFIA) and an enzyme-linked immunosorbent assay (ELISA), were developed to detect the hallucinogenic phenethylamine 2C-B and related drugs in urine. The LFIA provides rapid on-site screening with a detection limit of 15 ± 7 ng mL⁻¹, suitable for identifying recent exposure. The ELISA offers much higher sensitivity, with a detection limit of 6 ± 3 pg mL⁻¹, and its results closely match those from established UHPLC-MS-MS analysis, making it reliable for quantitative confirmation in toxicology. Both methods address the need for simple, cost-effective tools to monitor these dangerous substances.
In cynomolgus monkeys, noribogaine—a drug being developed for opioid dependence—did not cause seizures or EEG signals that warn of increased seizure risk, even at the highest dose tested (320 mg/kg). Monkeys showed mild behavioral effects such as reduced activity, scratching, licking, chewing, and some poor coordination. One monkey had brief myoclonic movements at the high dose, but these did not spread or link to EEG abnormalities. In contrast, the positive control pentylenetetrazol consistently triggered seizure-related EEG patterns and generalized seizures. The study establishes 320 mg/kg as the EEG no observed adverse effect level for noribogaine in this model.